CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · General Reference

Bazedoxifene/conjugated estrogens

combination drug

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionSep 28, 2025
Entity authorityQ16274732 ↗
Source-derived summary

Bazedoxifene/conjugated estrogens, sold under the brand name Duavee among others, is a fixed-dose combination medication for the treatment of menopause symptoms and postmenopausal osteoporosis. It contains the selective estrogen receptor modulator bazedoxifene and conjugated estrogens. It is taken by mouth.

The combination was approved for medical use in the United States in October 2013, and in the European Union in December 2014.

Editorial summary

“Bazedoxifene/conjugated estrogens” enters the record as combination drug. Crown Archives preserves that source wording while asking what Bazedoxifene, conjugated and estrogens can confirm, complicate or overturn.

Editorial reviewA dependable orientation record for establishing vocabulary, names and a first evidence trail. The current lead gives the account dated anchors—2013, 2014—that can be checked directly. The selected authority fields contribute no independent date. Its strongest next move is a source search built around Bazedoxifene, conjugated and estrogens.
Editorial analysis

Why this record matters

“Bazedoxifene/conjugated estrogens” is worth following because a concise public description often conceals a longer documentary argument. Here, Bazedoxifene, conjugated and estrogens provides the most credible route into that argument.

Evidence profile

Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Sep 28, 2025. The linked authority identifier is Q16274732. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2013 and 2014.

Critical limits

The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “Bazedoxifene/conjugated estrogens”, its source revision and the description used here.
  2. Expand the search: follow Bazedoxifene/conjugated estrogens primary sources, Bazedoxifene/conjugated estrogens archive and Bazedoxifene research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Bazedoxifene/conjugated estrogens”?
  2. What terminology or title could unlock a more precise catalogue search?
  3. Which institution is responsible for the underlying evidence?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “Bazedoxifene/conjugated estrogens” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.